345630-40-2|SF1670，≥98%|Medlife|Medlife为MCE，Selleck，麦克林，阿拉丁试剂，罗恩试剂，Sigma，安耐吉试剂，泰坦等同类产品品牌，上海现货，高性价比小分子化合物

您当前的位置：

SF1670

PTEN抑制剂,SF1670 是一种有效的特异性的人第10号染色体缺失的磷酸酶及张力蛋白同源蛋白 (PTEN) 抑制剂。

目录号: PC15829 纯度: ≥98%

CAS No. :345630-40-2

商品编号	规格	价格	会员价
PC15829-5mg	5mg	¥1360.00	请登录
PC15829-10mg	10mg	¥1690.00	请登录
PC15829-50mg	50mg	¥5750.00	请登录
PC15829-10mM (in 1mL DMSO)	10mM (in 1mL DMSO)	¥1500.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称

SF1670

中文别名

N-(9,10-二氧代-9,10-二氢-菲-2-基)-2,2-二甲基丙酰胺;SF1670

英文名称

SF1670

英文别名

SF 1670;N-(9,10-Dioxo-9,10-dihydro-2-phenanthrenyl)-2,2-dimethylpropanami de;SF1670 (PTEN Inhibitor);SF-1670;N-(9,10-Dihydro-9,10-dioxo-2-phenanthrenyl)-2,2-dimethyl-propanamide;N-(9,10-Dioxo-9,10-dihydro-phenanthren-2-yl)-2,2-dimethylpropionamide;SF1670;PTP CD45 Inhibitor;PTPase CD45 Inhibitor;PTP Inhibitor XIX;Protein Tyrosine Phosphatase CD45 Inhibitor;SF1670(PTENinhibitor);SF1670?PTEN inhibitor?;HMS3653A12;BCP08444;N-(9,10-Dioxo-9,10-dihydro-phenanthren-2-yl)-2,2-dimethyl-propionamide

Cas No.

345630-40-2

分子式

C₁₉H₁₇NO₃

分子量

307.34

包装储存

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

生物活性

SF1670 is a potent and specific phosphatase and tensin homolog deleted on chromosome 10 (PTEN) inhibitor.

性状

Solid

IC50 & Target[1][2]

PTEN

体外研究(In Vitro)

SF1670 is a specific PTEN inhibitor with prolonged intracellular retention in neutrophils. SF1670 enhances PtdIns(3,4,5)P3 signaling in transplanted neutrophils. SF1670 also elevates Akt phosphorylation in murine cells. Consistent with the enhanced Akt phosphorylation, pretreatment with SF1670 also significantly augments PtdIns(3,4,5)P3 level in mouse neutrophils. SF1670-induced Akt hyperactivation is abolished in PTEN-null neutrophils, further demonstrating that this effect is mediated by specific inhibition of PTEN activity. At 500 nM fMLP stimulation, SF1670 (500 nM)–pretreated neutrophils show nearly 70% higher (maximal) superoxide production than untreated neutrophils. HCT116 cells are pre-treated with the PTEN inhibitor SF1670 (2 μM) for 24 h (untreated HCT116 cells served as control); treated cells are subsequently plated under non-adherent conditions with added MET (60 μM), Lun (2 μM), or Gen (2 μM). SF1670 binds to the PTEN active site, resulting in elevated phosphatidylinositol (3,4,5) triphosphate signaling.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

SF1670 (3 mg/kg; i.p.) triggers postconditioning after inducing cerebral global ischaemia (17 min) and reperfusion (24 h)‐induced injury via occlusion of both carotid arteries in mice.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Swiss albino male mice (bodyweight 25-30 g)
Dosage:	3 mg/kg
Administration:	Treatment with i.p.
Result:	Lead to attenuation of cerebral I/R-induced increase in thiobarbituric acid reactive substances (TBARS).

运输条件

Room temperature or refrigerated transportation.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

参考文献

[1]. Li Y, et al. Pretreatment with phosphatase and tensin homolog deleted on chromosome 10 (PTEN) inhibitor SF1670augments the efficacy of granulocyte transfusion in a clinically relevant mouse model. Blood. 2011 Jun 16;117(24):6702-13. [Information]

[2]. Montales MT, et al. Metformin and soybean-derived bioactive molecules attenuate the expansion of stem cell-like epithelial subpopulation and confer apoptotic sensitivity in human colon cancer cells. Genes Nutr. 2015 Nov;10(6):49. [Information]

[3]. Amarjot Kaur Grewal, et al. Neuroprotective effect of pharmacological postconditioning on cerebral ischaemia-reperfusion-induced injury in mice. J Pharm Pharmacol. 2019 Jun;71(6):956-970. [Information]

溶解度数据

体外研究:

DMSO : ≥ 50 mg/mL (162.69 mM)

* "≥" means soluble, but saturation unknown.

配制储备溶液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.2537 mL	16.2686 mL	32.5373 mL
5 mM	0.6507 mL	3.2537 mL	6.5075 mL
10 mM	0.3254 mL	1.6269 mL	3.2537 mL

产品不同，其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液；配成溶液后，建议分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，建议在 6 个月内使用，-20°C 储存时，建议在 1 个月内使用。

体内研究:

建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

建议依照次序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (8.13 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (8.13 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation